Fycompa yog cov tshuaj thawj zaug hauv chav kawm tshawb pom ntawm Eisai's Tsukuba Research Laboratories. Tus neeg sawv cev yog ib qho kev xaiv heev, tsis muaj kev sib tw AMPA receptor antagonist uas yog postulated los txo cov neuronal hyper-excitation txuam nrog qaug dab peg los ntawm kev tsom mus rau glutamate kev ua ntawm AMPA receptors ntawm postsynaptic membranes. Ob qhov ncauj formulations ntawm Fycompa muaj nyob rau hauv Nyiv: ib ntsiav tshuaj thiab ib tug zoo granule formulation. Vim muaj kev txhawj xeeb txog kev pheej hmoo ntawm qaug dab peg cuam tshuam nrog kev cuam tshuam ntawm kev tswj hwm thaum cov tshuaj tsis tuaj yeem noj ntawm qhov ncauj ib ntus, xws li thaum lub sijhawm phais, nws tau hais tias cov neeg mob qaug dab peg yuav tsum tau kho ntxiv los ntawm txoj kev uas tsis yog kev tswj hwm qhov ncauj.
Txij li thaum Fycompa tsuas yog AMPA receptor antagonist-based antiepileptic tshuaj, Eisai tau tsim cov kev txhaj tshuaj no kom tau raws li cov kev xav tau ntawm cov neeg mob uas tsis tuaj yeem siv qhov ncauj tswj hwm, thiab tau ua daim ntawv thov tshuaj tshiab ntxiv raws li txoj hauv kev tshiab ntawm kev tswj hwm lub Yim Hli 2022, coj rau qhov kev pom zoo no.
Ib chav tsev ntawm Fycompa® rau kev txhaj tshuaj intravenously, muaj 2.16 mg perampanel hydrate (eq. 2.08 mg ntawm perampanel), 1040 mg.SBECD, nrog rau phosphoric acid thiab sodium hydroxide rau pH teeb.
